Clinical Trials

ITOG Active Clinical Trials

Several important studies are underway for the investigation of various treatments for thyroid cancers.  Below is a list of active clinical trials in which ITOG members are participating.   Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers (Actively Recruiting)         Principal Investigator – Alan Ho, MD, PhD, Memorial Sloan-Kettering Cancer Center        Email: This is a randomized Phase II trial evaluating the... Continue reading

Cabozantinib as salvage therapy in differentiated thyroid cancer

The first clinical trial orchestrated by ITOG has been completed, marking a major achievement for the group.  This phase II trial, led by Dr. Manisha Shah from Ohio State University, found that patients who had progression of their thyroid cancer on a vascular endothelial growth factor receptor (VEGFR) inhibitor could benefit from treatment with cabozantinib. This work was recently published in the Journal of Clinical Oncology.  Traditional treatments for differentiated thyroid cancer (... Continue reading

Treatment with lenvatinib is associated with significant clinical improvement in patients with radioiodine-refractory differentiated thyroid cancer

A large, multi-center phase 3 study (SELECT trial) has found that patients with progressive, iodine refractory differentiated thyroid cancer have markedly improved progression free survival (PFS) when treated with lenvatinib, an oral tyrosine kinase inhibitor. Multiple ITOG members participated in the study, including lead author, Dr. Martin Schlumberger and senior author, Dr. Steven I. Sherman, current Chairman of ITOG.  The study, funded by the Eisai, the manufacturer of lenvatinib, was published in the New England Journal of Medicine, on February 12, 2015.On February 13th the FDA approved... Continue reading

ITOG Opens First Clinical Trial

ITOG is poised to open it’s first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGR inhibitor benefit from treatment with Cabozantinib.NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on first-line therapy with a VEGFR antagonist. ITOG’s first... Continue reading


International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495